Papers › Accurate structural modeling of chemically diverse molecular interfaces with Vilya-2
Accurate structural modeling of chemically diverse molecular interfaces with Vilya-2
Vilya Research, :, Pascal Sturmfels, Naozumi Hiranuma, Milad Salem, Benjamin D. Sellers, Stephen Rettie, CJ San Felipe, Chase A. P. Wood, Jeffrey K. Holden, Adam P. Moyer, Patrick J. Salveson, Ivan Anishchanka
Title, abstract, authors and date from arXiv's metadata (CC0); this paper is not in the Papers with Code archive (frozen 2025-07-28).
Structure-prediction networks built on co-evolutionary statistics have transformed protein-based drug discovery, yet their accuracy does not extend to peptide therapeutics--an increasingly important modality defined by non-canonical residues, macrocyclization, and complex topologies. We introduce Vilya-2, a diffusion transformer that extends the all-atom representation of Vilya-1 from modeling individual molecules to modeling their interactions with protein targets. This all-atom representation enables transfer learning between different molecular types, and delivers highly accurate structural modeling of peptides across sizes, classes, and compositions bound to therapeutically relevant targets. By generating diverse structural ensembles and ranking them with calibrated confidence, Vilya-2 recovers 59.1% of peptide interfaces to sub-2 Å backbone RMSD, far exceeding the performance of a representative co-folding model even when that model is given the bound receptor as a template. In addition, Vilya-2 is state-of-the-art at small-molecule docking, and generalizes to novel protein-small molecule complexes unlike those seen in training. It also generalizes to modeling molecular conformations of diverse macrocycles and disulfide-stapled miniproteins several-fold larger than any molecule seen in training. Finally, Vilya-2 can be used as a foundation model, and fine-tuned to enrich for active compounds in hit-to-lead campaigns. By unifying predictive accuracy with broad generalizability across chemical space, Vilya-2 is the structure-prediction oracle that de novo peptide design pipelines require--establishing the all-atom approach as a general foundation for the design and evaluation of de novo peptide therapeutics.
Code
Reachability, where shown, is from one Syntology probe window (2026-09-16 to 2026-09-18); repositories not probed show nothing. GitHub stars are not tracked.
Code Syntology ran Syntology
Syntology holds the repository link but has not harvested or run code from it.
Results from the paper
The Papers with Code archive ends with its 2025-07-28 snapshot. This paper's arXiv identifier, 2607.25156, was issued in July 2026, after that date, so the archive has no leaderboard rows for it.
Report a problem or propose a change · a person checks every report against the paper or source before anything changes; decisions are listed on /corrections